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Abstract
The aim. The aim of the study was to conduct a comparative analysis of fibroblast growth factor-2, the total content and 
fractions of sulfated glycosoaminoglycans as well as free and peptide-bounding oxyproline as the markers of connective tissue me-
tabolism in young patients with mitral valve prolapse, type 1 diabetes mellitus and the combination of both indications.
Materials and methods. 93 patients between 19 and 33 years old with either mitral valve prolapse, or type 1 diabetes or 
the combination of both indications were examined. Group 1 was represented by 36 patients with the monomorbid type 1 diabetes 
mellitus. Group 2 consisted of 33 patients with type 1 diabetes mellitus and mitral valve prolapse. The comparison group included 
24 people with diagnosed mitral valve prolapse. The concentration of fibroblast growth factor-2 in blood plasma was determined by 
the enzyme immunoassay using a Quantikine reagent kit (Human FGF basic Immunoassay), manufactured by R&D Systems, Inc. 
(USA) and expressed in pg/ml. The total content and fractions of glycosaminoglycans in blood serum were determined by the method 
of N. G. Stern et al. and expressed in units of optical density. The level of free and peptide-bounding oxyproline in blood serum were 
determined by the method of P. N. Sharaev and expressed in µmol/L.
Results. Fibroblast growth factor-2 was higher in group 2, where it was 23.7 ± 0.25 pg/ml compared to the control group – 
14.20 ± 0.22 pg/ml (p < 0.01). There was also a significant difference in the levels of fibroblast growth factor-2 between groups 1 
where it equaled 15.33 ± 0.24 pg/ml and 2 – 23.71 ± 0.25 pg/ml (p < 0.01). The total content of glycosaminoglycans in comparison 
with the control group, where it was equal to 9.7 ± 0.62 odu, was higher in all groups of patients: in group 1 it was 12.07 ± 1.04 odu, 
in the comparison group it was 11.75 ± 0.83 odu, in the group with the combined pathology it was 13.32 ± 1.59 odu (p < 0.05). The 
values of glycosaminoglycans II fraction, were higher in group 2 – 4.96 ± 0.59 odu. The level of peptide-bound oxyproline, just as 
the level of free oxyproline, significantly increased in patients with comorbid pathology in group 2, compared to the control group: 
16.06 ± 1.54 µmol/l versus 8.7 ± 0.81 µmol/l (p < 0.01) respectively.
Conclusions. The values of fibroblast growth factor-2, glycosaminoglycans II fraction, free and peptide-bound oxyproline 
were significantly higher in patients with diabetes mellitus and mitral valve prolapse in comparison with the control group. Fibroblast 
growth factor-2 was higher in patients with comorbid pathology compared to the monomorbid diabetes patients.




Connective tissue is one of the most prevalent and functionally loaded tissue structures in 
the body. It actively participates in the regulation of metabolic processes, providing the synthesis 
and secretion of cytokines, growth factors, tissue hormones, enzymes, etc. Furthermore, it has 
a regulatory effect on reproduction, differentiation of cells, the intercellular substance metabo-
lism and, as a consequence, the formation of organ structures at the embryonic and postnatal de-
velopment stages. The regenerative properties of fibroblasts provide the plastic function of the 
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connective tissue. Connective tissue is represented by a cellular component, fibrillar structures (col-
lagen, elastin), as well as glycoproteins and proteoglycans. Glycosoaminoglycans (GAGs) are the 
carbohydrate part both of glycoproteins and proteoglycans and form the extracellular matrix [1, 2]. 
The physicochemical properties of collagen change under pathological influences [3]. Oxyproline 
is one of the main aminoacids of collagen, which makes free oxyproline and peptide-binding oxy-
proline one of the most significant biomarkers of collagen metabolism [4]. 
An increased content of free oxyproline in the blood may indicate collagen hypercata bolism. 
Peptide-binding oxyproline is a product of incomplete collagen decay. It is indirectly asso ciated 
with the presence of atypical pathological forms of collagen and the processes of degradation of 
connective tissue. Accordingly, the ratio of the free and peptide-binded oxyproline to a certain ex-
tent reflect, the tendencies of increased synthesis or pathological decomposition of collagen, which 
can take place simultaneously [5].
The sulfated GAGs, which are the primary markers of connective tissue dysplastic proces-
ses, take a special place in the metabolic processes of connective tissue. GAG fractions are specific 
according to various tissue structures. The GAG fraction I is found mainly in cartilage, tendons and 
ligaments. The main substance of the connective tissue of the heart valve apparatus is represented 
by the GAG fraction II. The GAG fraction III is involved in the structure of the basal membranes 
of blood vessels [6].
Fibroblast growth factors (FGF) take their place in the regulation of metabolic processes 
of connective tissue, among which fibroblast growth factor-2 (FGF-2) is tropic to heart valve ap-
paratus. Some research is being done on the role of FGF-2 in relation to its direct participation in 
the formation of pathological disorders of connective tissue of cardiac structures during embryo-
genesis and in the postnatal period [7]. However, the studies of the FGF-2 role in morphofunctional 
changes development in valves and myocardium due to dysmetabolic change, in comparison with 
proteoglycan parameters of connective tissue metabolism combined with mitral valve prolapse are 
insufficient. 
Mitral valve prolapse (MVP) is one of the most common cardiac manifestations of the un-
differentiated dysplasia of connective tissue [8, 9], which is considered as a separate nosological 
unit [10]. In case of the predominantly positive clinical picture of mitral valve prolapse, the quality 
of life and the mental condition are deteriorating upon the complicated course [11]. Should the de-
velopment of myxomatous degeneration of the heart valve apparatus be associated with it, there is 
a threat of heart failure as well as syncope [12, 13]. MVP is the main cause of cardiac surgery for 
mitral regurgitation and high-grade arrhythmias [14, 15]. Myxomatous degeneration of heart valve 
apparatus is caused by genetically determined and phenotypic disorders of metabolic processes in 
connective tissue [16, 17]. The causes of damage to the spongiosa of mitral valve are an increase 
in the level of hydration through GAG and fibrillogenesis disorder, indicated by oxyproline me-
tabolism and influenced by FGF-2. These factors lead to the microstructure disorder as well as the 
functional ability of the mitral valve [7]. 
In case of diabetes mellitus (DM), dysmetabolic processes of connective tissue and of the 
carbohydrate metabolism develop simultaneously and are interdependent. Connective tissue dys-
plasia can be a background for the development and progression of diabetes. In turn, microvascular 
damages that are inherent in diabetes can deepen degenerative processes in the heart valve appara-
tus. Thus, the relationship between connective tissue dysplasia, the main cardiac manifestation of 
which being MVP, and the development of diabetes may be quite expected [18]. 
The aim: to perform a comparative analysis of FGF-2, the total content and fractions of 
sulfitized GAGs as well as free and peptide-bounding oxyproline as the markers of connective 
tissue metabolism in young patients with mitral valve prolapse, type 1 diabetes mellitus and the 
combination of both indications.
2. Materials and methods
93 patients between 19 and 33 years old with either MVP, or type 1 diabetes mellitus (DM1) 
or the combination of both indications were examined (average age of the examined patients was 
26.3+0.94). Overall 69 patients suffered from diabetes. Group 1 was represented by 36 patients 
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with the monomorbid DM1. Group 2 consisted of 33 patients with DM1 and MVP. The comparison 
group included 24 people with diagnosed MVP. In group 1 the average age was 27.43 ± 1.17 years, 
in group 2 it laid by 26.88 ± 1.05 years, in comparison group it was 23.9+1.3 years. The control 
group included 22 virtually healthy individuals. The patients were in inpatient treatment in the 
endocrinology department of the CNС KhRC «Regional Clinical Hospital». The research was con-
ducted during 2017–2020. 
During the study the principles of the Declaration of Helsinki adopted by the General As-
sembly of the World Medical Association (1964–2000), the Council of Europe Convention on Hu-
man Rights and Biomedicine (1997), the relevant provisions of the WHO, the International Council 
of Medical Scientific Communities, the International Code of Medical ethics (1983) and the laws 
of Ukraine were followed. It was approved by ethics committee at Kharkiv Medical Academy of 
Postgraduate Education (protocol No. 8 of 27.09.2017). All patients voluntarily signed an informed 
consent before starting the study.
The diagnosis of type 1 diabetes was established according to the order of the Ministry of 
Health of Ukraine No. 1021 from 27th of June, 2014 [19]. The diagnosis of MVP and the main indica-
tors of EchoCG were established according to the echocardiographic criteria of L. Freed et al. (2002) 
and Bonow R. O. et al., (2006) [20, 21]. 
The concentration of FGF-2 in blood plasma was determined by the enzyme immunoassay 
using a Quantikine reagent kit (Human FGF basic Immunoassay), manufactured by R&D Systems, 
Inc. (USA) and expressed in pg/ml. The total content and fractions of GAGs in blood serum were 
determined by the method of N. G. Stern et al. [22] and expressed in units of optical density. The 
level of free and peptide-bounding oxyproline in blood serum were determined by the method of 
P. N. Sharaev [23] and expressed in µmol/L. Furthermore, the ratio of free and peptide-bounding 
oxyproline was calculated. 
Statistical data processing was implemented using the methods of variation statistics and 
the Statistica 6.0 software package. Unpaired Student’s t-test was used when comparing the results, 
depending on the normality of the distribution, to identify significant differences. The significance 
level for testing statistical hypotheses when comparing groups was < 0.05.
3. Results
There is a change in the physicochemical properties of collagen and proteoglycans in dys-
plastic processes of connective tissue, leading to activation and proliferation of the connective 
tissue cellular component and, furthermore, to the activation of proteolytic enzymes as well as to 
the deformation of the structural collagen fibers [5, 15]. 
The content of free oxyproline, which is the marker of collagen synthesis and degradation, 
significantly increased in patients of group 2 with a combination of type 1 diabetes mellitus and 
mitral valve prolapse, compared to the control group, (p < 0.05) (Table 1). When comparing groups 
of patients with each other, no significant differences were found in terms of free oxyproline. The 
value reflects the process of collagen degradation. An increase in the content of free oxyproline 
in patients with concomitant pathology may indicate an increase in the intensity of destructive 
processes in the collagen metabolism, which corresponds to the presence of a subclinical chronic 
inflammatory process of low intensity and is a pathological part of the development of diabetes 
vascular complications (Table 1).
The peptide-bound oxyproline was more informative as a marker of pathological synthe-
sis and incomplete collagen decomposition. The level of peptide-bound oxyproline, just as the 
level of free oxyproline, significantly increased in patients with comorbid pathology in group 2, 
compared to the control group: 16.06 ± 1.54 µmol/l versus 8.7 ± 0.81 µmol/l (p < 0.01) respectively. 
Also, a significant increase in measured values of peptide-bound oxyproline in this group could 
be determined in comparison with group 1 where it was 12.38 ± 1.34 µmol\L and the comparison 
group – 10.18 ± 1.85 µmol\L (p < 0.05).
The ratio of free oxyproline and peptide-bound oxyproline levels, which reflects the ba-
lance of collagen synthesis and degradation, was [25.9 %] lower in patients of group 2 than in the 
comparison group and significantly lower than in the control group by [35.7 %] due to the relative 
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increase in the proportion of peptide-bound oxyproline. The data obtained indicate a relative im-
balance of the connective tissue anabolism and catabolism in case of a combination of diabetes 
and MVP. Furthermore, it is an indication for the increased pathological changes in the connective 
tissue metabolism, which can lead to remodelling and myxomatous degeneration of its structure. 
Table 1
Levels of free oxyproline and peptide-bound oxyproline in the blood serum of patients with MVP, DM1 and 
the combination of both





















The ratio of free oxypro-
line and peptide-bound 
oxyproline
1.22 1.12 1.41 1.52
Note: the index r of the p-value corresponds to the reference value. The indices 1, 2 and 3 correspond to the numbers of the com-
parison groups
GAG changes are primary relative to the onset of collagen degradation processes. They 
advance fibrillogenesis, since the disruption of biopolymer synthesis is secondary to the proteogly-
cans metabolism, which are significantly influenced by growth factors, namely FGF-2. 
The total content of GAG in comparison with the control group, where it was equal 
to [9.7 ± 0.62] odu, was higher in all groups of patients: in group 1 it was [12.07 ± 1.04] odu, 
in the comparison group it was [11.75 ± 0.83] odu. In the group with the combined pathology it 
was even higher [13.32 ± 1.59] odu, (p < 0.05). The values of GAG II fraction, which is represen-
ted in the main substance of the heart valve apparatus, were higher in group 2 and the compa-
rison group [4.96 ± 0.59] odu and [4.35 ± 1.83] odu respectively, compared to the control group 
[3.14 ± 0.2] odu (p < 0.05). The values of GAG III fraction were higher in diabetes patients in group 
1 and 2. This is reliably due to the presence of heparan sulfate in the lamina densa of the basal mem-
branes of blood vessels, which is a part of the GAG III fraction, and may indicate microangiopathic 
complications (Table 2).
Fibroblast growth factor-2 was higher in group 2, where it was 23.7 ± 0.25 pg/ml and 
in the comparison group, where it was equal to 18.11 ± 0.21 pg/ml, compared to the control 
group – 14.20 ± 0.22 pg/ml (p < 0.01). There was also a significant difference in the levels of 
FGF-2 between groups 1 and 2 in diabetes patients. It was equal to 15.33 ± 0.24 pg/ml and reached 
23.71 ± 0.25 pg/ml respectively, probably due to the presence of MVP in the group with comorbid 
pathology (p < 0.01). 
In patients with a diabetes duration over 10 years from the moment of clinical manifesta-
tion (n = 30), the value of FGF-2 was 19.71 ± 0.25 pg/ml, significantly exceeding this indicator in 
32 patients with a diabetes duration under 10 years – 18.89 ± 0.21 pg/ml, p < 0.05. A high level 
of FGF-2 was observed in the subgroup of patients with comorbid pathology with diabetes duration 
over 10 years: 24.22 ± 0.49 pg/ml versus 14.20 ± 0.22 pg/ml in the control group (p < 0.01).
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The content of GAGs and its fractions in the blood serum of patients with type 1 diabetes, MVP and its 
combination
Indicators Group 1  (monomorbid DM1)






























Note: the index r of the p-value corresponds to the reference value. The indices 1, 2 and 3 correspond to the numbers of the com-
parison groups
4. Discussion
The level of free oxyproline reflects the processes of collagen degradation [6], while pep-
tide-bound oxyproline additionally represents the intensity of pathological collagen syn thesis. 
Autoregulation of connective tissue metabolism is based on a correlation between the synthe-
sis and catabolism of collagen. A simultaneous increase in the level of free oxyproline and pep-
tide-bound oxyproline, which was higher in diabetes patients, may indicate a violation of this au-
toregulatory mechanism. As a result of increasing in the intensity of destructive processes in the 
connective tissue can be the activation of inflammation. It is known that even low intensity of 
chronic inflammation is one of the important mechanisms in the diabetes mellitus development 
and its vascular complications. Changes in physicochemical properties concern not only collagen, 
but also GAGs (carbohydrate components of proteoglycans), which were higher among patients 
with MVP.
The obtained data indicated the informative value of significant differences between the 
groups of patients and the control group relative to the GAG II fraction, both in combined pa-
thology and in monomorbid MVP, as well as to the GAG III fraction in diabetes, when compared 
with the comparison group. FGF-2 indices were significantly higher in the group with comor-
bid pathology, probably due to the presence of MVP (p < 0.01). Also, FGF-2 was significantly 
higher in case of the diabetes duration of more than 10 years from the moment of clinical mani- 
festation (p < 0.05). 
Study limitations. Relatively long time for the examination of patients with comorbid pa-
thology in comparison with monomorbid groups of patients.
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Prospects for further research. The research will be further continued by a study of colla-
gen metabolism indicators, FGF-2, GAGs, free and peptide-bound oxyproline and its comparison 
with indicators of intracardiac kinetics of the left ventricle.
5. Conclusions
1. The content of free and peptide-bound oxyproline in the blood serum of the examined 
patients compared with the control group was significantly higher in patients with type 1 diabetes 
combined with MVP (p < 0.05).
2. A significant increase of peptide-bound oxyproline in group 2 in comparison to group 1 
and the comparison group was identified: 12.38 ± 1.34 µmol\L and 10.18 ± 1.85 µmol\L respecti-
vely (p < 0.05).
3. Levels of GAG II fraction were significantly higher in groups with MVP: 
4.96 ± 0.59 (group 2) and 4.35 ± 1.83 (comparison group), compared with the control group where 
it reached 3.14 ± 0.2 (p < 0.05). 
4. GAG III fraction was prevailing in diabetic patients, regardless of the presence or absence 
of MVP, and was reliably associated with the development of diabetic microangiopathies. 
5. FGF-2 in patients of group 2 were significantly higher compared to the control group, 
group 1 and the comparison group. They were also significantly lower in group 1 compared to the 
comparison group.
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